00000nam 2200000zi 4500 9.871535 CaOODSP 20221107163421 m o d f cr ||||||||||| 190412e20190402onc #o f000 0 eng d CaOODSP eng rda CaOODSP n-cn--- YN5-176/2019E-PDF The impact of the Canada-United States-Mexico Agreement on prescription drug expenditures in Canada. Ottawa, Canada : Office of the Parliamentary Budget Officer = Bureau du directeur parlementaire du budget, 2 April 2019. 1 online resource (37 pages). text txt rdacontent computer c rdamedia online resource cr rdacarrier Issued also in French under title: Incidence de l'Accord Canada-États-Unis-Mexique sur les dépenses en médicaments d'ordonnance au Canada. Cover title. Includes bibliographical references. "The Canada-United States-Mexico Agreement (CUSMA) provides an extension to the term of protection for data resulting from drug trials. The extension applies to a category of pharmaceuticals known as innovative biologics. These are drugs with complex structures that have become increasingly popular. In recent years, pharmaceutical companies have been seeking extensions to the terms of data protection for such biologics to bolster the market exclusivity given by patents"--Executive summary, page 1. gccst Trade agreements gccst Drugs Canada. Office of the Parliamentary Budget Officer. Incidence de l'Accord Canada-États-Unis-Mexique sur les dépenses en médicaments d'ordonnance au Canada. (CaOODSP)9.871626 PDF 870 KB https://publications.gc.ca/collections/collection_2019/dpb-pbo/YN5-176-2019-eng.pdf